Literature DB >> 1321598

Does the extent of surgery make a difference in high grade malignant astrocytoma?

C I Franklin1.   

Abstract

This paper examines the effect of patient age, tumour grade and extent of surgery on the outcome of treatment of 278 patients with high grade malignant gliomas referred to the Queensland Radium Institute between 1980 and 1987. The aim was to determine whether the extent of surgical resection alters survival rates. The extent of surgery had no effect on survival except for those patients with grade 3 tumours in whom a total excision was possible. Those in whom only a biopsy was done did not have a worse prognosis. Grading was found to be of importance, as patients with grade 3 tumours had a better survival than those with grade 4 tumours. In grade 4 tumours, those under 30 years of age had a better survival than those over 30 years, whereas with grade 3 tumours there was a gradation of age effect (under 40 years best, then 40-49 years, and those 50 years and over doing worst.

Entities:  

Mesh:

Year:  1992        PMID: 1321598     DOI: 10.1111/j.1440-1673.1992.tb03073.x

Source DB:  PubMed          Journal:  Australas Radiol        ISSN: 0004-8461


  4 in total

1.  Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-10-31       Impact factor: 4.130

2.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Authors:  Graziella Filippini; Chiara Falcone; Amerigo Boiardi; Giovanni Broggi; Maria G Bruzzone; Dario Caldiroli; Rita Farina; Mariangela Farinotti; Laura Fariselli; Gaetano Finocchiaro; Sergio Giombini; Bianca Pollo; Mario Savoiardo; Carlo L Solero; Maria G Valsecchi
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

3.  Multicentre prospective collection of newly diagnosed glioblastoma patients: update on the Lombardia experience.

Authors:  Andrea Salmaggi; Antonio Silvani; Rossella Merli; Manuela Caroli; Giustino Tomei; Annamaria Russo; Maurizio Riva; Enrico Marchioni; Francesca Imbesi
Journal:  Neurol Sci       Date:  2008-05-16       Impact factor: 3.307

4.  Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and PTEN Genes.

Authors:  Sajad Hussain Arif; Arshad Ahmad Pandith; Rehana Tabasum; Altaf Umar Ramzan; Sarabjeet Singh; Mushtaq Ahmad Siddiqi; Abdul Rashid Bhat
Journal:  Asian J Neurosurg       Date:  2018 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.